In development

LelekaBio™

Prediction based on biology. AI-powered. Patient-driven.
An AI-powered platform for predicting drug response and resistance, built on patient-derived tumor biology.

Our mission

Named after the Ukrainian word for stork, a symbol of new beginnings, LelekaBio™ in on a mission to bring new life to oncology drug discovery.

In a landscape where over 90% of cancer drugs fail in clinical trials, we bridge real patient biology and AI-powered prediction to accelerate development of more effective and reliable precision therapeutics.

customer value

Built for Every Oncology Team

R&D teams

Prioritize leads with higher clinical success likelihood
Validate targets on human-relevant models
Identify resistance early, guide combination therapy

Translational & Biomarker Teams

Correlate model response with patient stratification markers
Develop and test companion diagnostics preclinically

AI & Data Teams

Access deeply annotated, high-quality biological training sets
Use digital twin predictions to complement internal algorithms

What is Lelekabio?

Leleka Bio integrates patient-derived 3D tumor models with cutting-edge AI to simulate drug response and resistance before clinical trials.
Unlike AI-first platforms that rely on synthetic or public datasets, Leleka Bio grounds its insights in fresh patient tumors — capturing clinically relevant phenotypes and omics data.

App Layer — Secure SaaS

Drug efficacy prediction
Resistance mechanism identification
Lead prioritization
Clinical trial design support

AI/ML Model — Supervised Learning

Molecular profiles in vitro and in vivo
Drug responses in vitro vs. clinic
AI-powered pattern detection on internal data

Data Layer — Proprietary Biological Data

Full ownership of surgical tissue sources & 3D organoids
In vitro drug screens using 3D organoid
RNAseq molecular profiling with matching clinical data

LelekaBio - AI powered platform structure lowest level is proprietary Biological data, Mid level is an ML model and top layer is application layer.

LelekaBio Advantages

What Sets Leleka Bio Apart

Real Tumors
Not Cell Lines

In Silico Drug
Response Prediction

Multi-Omics
Functional Validation

Bioprinting-Ready
for the Future

Contract research organization, which provides solutions for pharma and diagnostics companies, including consulting, cancer models development, and various assays for drug development.

contact

28047 Dorothy Drive, #204,
Agoura Hills, CA 91301, USA

Call: +1 442-224-3375

E-mail: Info@drlus.com

Services

Biobank

Assays

LelekaBio

Support & Expertise

company

About Us

Team

Blog

Resources

Contact